European Journal of Nuclear Medicine

, Volume 20, Issue 2, pp 101–106 | Cite as

Uptake and distribution of L-3-[I-125] Iodo-α-methyl tyrosine in experimental rat tumours: comparison with blood flow and growth rate

  • Brian Deehan
  • Paul Carnochan
  • Manu Trivedi
  • Amanda Tombs
Original Article


Radiolabelled amino acids combined with positron emission tomography (PET) show promise for the accurate delineation of viable tumour extent and may also provide a rapid and sensitive indicator of response to therapy. We have investigated the potential use of the radioiodinated amino acid analogue L-3-iodo-α-methyl tyrosine (IMT) for these purposes using experimental tumours in hooded rats. Preliminary studies using HSN tumours and IMT labelled with iodine-125 demonstrated maximum tumour uptake at 15 min post injection although an improved tumour-to-brain ratio was seen at 24 h due to the relatively poor retention of IMT in normal brain. Brain uptake of IMT was also found to be substantially reduced by competition with another large neutral amino acid phenylalanine; however, relatively less effect was seen in tumour, and in skeletal muscle no change in IMT uptake was observed. Quantitative autoradiography revealed no sign of heterogeneity in tumour IMT uptake: good penetration was seen even in poorly vascularised regions as confirmed by endothelial immunohistochemistry. Similar levels of IMT uptake were found in the OES.HR1 tumour during growth supplemented by exogenous oestrogen. Following arrest of tumour growth by removal of the oestrogen stimulus, IMT uptake was seen to fall from 1.7% to 1.0% of the injected dose per gram: this was matched by a fall in tumour blood flow as estimated by technetium-99m hexamethylpropylene amine oxime distribution. It appears that IMT uptake is more strongly influenced by blood flow than cell proliferation and that intratumoural distribution of IMT is principally determined by diffusion.

Key words

Iodomethyltyrosine Tumour imaging 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abe Y, Matsuzawa T, Itoh M et al. (1988) Regional coupling of blood flow and methionine uptake in an experimental tumour assessed with autoradiography. Eur J Nucl Med 14:388–392.Google Scholar
  2. Bergström M, Collins VP, Ehrin E et al. (1983) Discrepancies in brain tumour extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 7:1062–1066.Google Scholar
  3. Biersack HJ, Coenen HH, Stöcklin G et al. (1989) Imaging of brain tumours with l-3-[123I]iodo-α-methyl tyrosine and SPECT. J Nucl Med 30:110–112.Google Scholar
  4. Bolster JM, Vaalburg W, Paans AMJ et al. (1986) Carbon-11 labelled tyrosine to study tumour metabolism by positron emission tomography (PET). Eur J Nucl Med 12:321–324.Google Scholar
  5. Hammersley PAG, McCready VR, Babich JW et al. (1987) 99mTc-HMPAO as a tumour blood flow agent. Eur J Nucl Med 13:90–94.Google Scholar
  6. Kawai K, Fujibayashi Y, Saji H et al. (1991) A strategy for the study of cerebral amino acid transport using iodine-123-labeled amino acid radiopharmaceutical: 3-iodo-alpha-methyl-l-tyrosine. J Nucl Med 32:819–824.Google Scholar
  7. Kloster G, Bockslaff H (1982) l-3-123I-α-methyltyrosine for melanoma detection: a comparative evaluation. Int J Nucl Med Biol 9:259–269.Google Scholar
  8. Kloster G, Coenen HH, Szabo Z et al. (1982) Radiohalogenated l-α-methyltyrosines as potential pancreas imaging agents for PELT and SPECT. In: Cox PH (ed) Progress in radiopharmacy, vol 3. Martinhus Nijhoff, Den Haag, pp 97–107.Google Scholar
  9. Kubota K, Ishiwata K, Kubota R et al. (1991) Tracer feasibility for monitoring radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, l-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. J Nucl Med 32:2118–2123.PubMedGoogle Scholar
  10. Langen K-J, Coenen HH, Roosen N et al. (1990) SPECT studies of brain tumours with l-3-[123I]iodo-α-methyl tyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med 31:281–286.Google Scholar
  11. Langen K-J, Roosen N, Coenen HH et al. (1991) Brain and brain tumour uptake of l-3-[123I]iodo-α-methyl tyrosine: competition with natural l-amino acids. J Nucl Med 32:1225–1228.PubMedGoogle Scholar
  12. Richter JJ, Wainer A (1971) Evidence for separate systems for the transport of neutral and basic amino acids across the blood-brain barrier. J Neurochem 18:613–620.Google Scholar
  13. Smith TAD, Eccles S, Ormerod MG et al. (1991a) The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rate. Br J Cancer 64:821–826.Google Scholar
  14. Smith TAD, Eccles S, Ormerod MG et al. (1991b) Proliferation rate is strongly associated with the phosphocholine and glycerophosphorylcholine content of an oestrogen-sensitive rat mammary tumour. Proceedings of the 10th Meeting of the Society of Magnetic Resonance in Medicine, San Francisco, Calif., p 34.Google Scholar
  15. Tisljar U, Kloster G, Ritzl F et al. (1979) Accumulation of radioiodinated l-α-methyltyrosine in pancreas of mice: concise communication. J Nucl Med 20:973–976.Google Scholar
  16. Wienhard K, Herholz K, Coenen HH et al. (1991) Increased amino acid transport into brain tumours measured by PET of l-(2-18F)fluorotyrosine. J Nucl Med 32:1338–1346.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Brian Deehan
    • 1
  • Paul Carnochan
    • 1
  • Manu Trivedi
    • 1
  • Amanda Tombs
    • 2
  1. 1.Department of Physics, Institute of Cancer ResearchRoyal Cancer HospitalBelmont, SuttonUK
  2. 2.Immunology Section, Institute of Cancer ResearchRoyal Cancer HospitalBelmont, SuttonUK

Personalised recommendations